PTU - Polskie Towarzystwo Urologiczne
list of articles:

High dose rate brachytherapy combined with external beam radiotherapy in the treatment of prostate cancer patients
Article published in Urologia Polska 2003/56/1.


Zbigniew Wolski 1, Andrzej Wronczewski 1, Roman Makarewicz 2, Anna Wronczewska 2
1 Raledra i Klinika Urologii Akademii Medycznej im. L. Rydygiera w Bydgoszczy
Kierownik katedry i kliniki: prof, AM dr hab. Zbigniew Wolski
2 Katedra i Zakład Onkologii Akademii Medycznej w Bydgoszczy i Oddział Brachyterapii Regionalnego Centrum Onkologii
Kierownik zakładu: prof. AM dr hab. Roman Makarewicz


prostate, prostate cancer, high dose rate brachytherapy


Introduction. Ap;irl from radical prostatectomy and external beam radiotherapy (EBRT), brachytherapy (BT) is one of the method of treatment of prostate cancer patients. II consists in transient or constant interstitial prostate irradiation with the use of different isotopes.
The aim of the study The aim of this study is to present our own results of transitional high dose rate brachytherapy (BT HDR) of iridium isotope 1192 combined with external beam radiotherapy (EBRT).
Material and method. From 2000. BT + EBRT has been performed according to our system, e.g. 2 BT fractions of 10 Gy + 2 3 EBRT sessions of 2 Gy + 2 BT fractions of 10 Gy. We used this mode of treatment in Y2 patients aged from 58 to 79 years with prostate cancer stage cTl-c\'l\'2-cT3ab NO MO, (II-J and serum PSA levels from 2 to 37,5 ng/ml (mean 12.3 ng/ml). The tolerance and complications of the treatment, as well as serum PSA levels 1 month and every 3 months after completion of radiotherapy were estimated.
Results. The follow-up ranged from 6 to 24 months. Except of transient hematuria in 4 patients, there were no complications of BT. Frequency was noted in 11 patients during EBRT. None of patients had symptoms of urinary retention, urinary incontinence or distant metastases. All patients are still alive without symptoms and signs of neoplasl ic disease. In 2 3 patients {72%) serum PSA levels decreased below 0.5 ng/ml.
Conclusions. The preliminary results of high rate dose of brachytherapy combined with external beam radiotherapy show that BT is a safe method.
In majority of patients rapid decrease of serum PSA levels a in short time was observed. Thus, brachytherapy seems to be an efficient method.


  1. 1. Lewanski CR: Brachyterapia w raku stercza: ponowne zastosowanie starej techniki. Current Medical Literature, Urologia 2002; 5: 40-46.
  2. 2. Plowmann PN: Metody radykalne} radioterapii raka stercza ograniczonego do stercza. BJU Inter Kur Urol Update Scries 2001: 2: 19-29.
  3. 3. Ravery V: Brachyterapia przeciw prostatektomii radykalnej. BJU Inter Eur Urol Update Series 2001; 1:12-14.
  4. 4. Grimm P. Blasco J. Sylvester J. Meier R. Canavagh W: 10-year biochemical (PSA) control of prostate cancer with 1251 brachytherapy. In I J Raddial Oncol Biol Phys 2001; 51: 31-40.
  5. 5. Deger S. Boehmer 0. Turk I. Roigas J. Wernecke K. Wicgel T. Hinkei-bein W. Hinges S. Budach V, Loening S: High dose rale brachytherapy of localized prostate cancer. Bur Uro 2002:41:420-426.
  6. 6. Loch T. Kovacs G, Stockle M: Brachytherapy in localised prostatic cancer: 100 years of radium. Current Opinion of Urology 1998; 8. 5: 387-392\"
  7. 7. American Health Consultation: Biomed Bus Intl Newsletter 1997: 20, 1.3:36.
  8. S. Korb L: Ten year disease fie survival after iransperineal sonography -guided iodine-12 5 brachytherapy with or without 45-Gray external beam irradiation in the. treatment of patients with clinically localized, low to lugh gleason grade prostate carcinoma. Cancer 1998: S3. 1: 989-1001.
  9. 9. Morion R. Sleiner M. Walsh P: Cancer control following anatomical radical prostatectomy. JUrol 1991: 145:1197-1200.
  10. 10. Zictman A, Shipley VV. WillettC: Residual disease after mdicid surgery or radiation for prostate cancer. Cancer 1993:71: 9 59-969.
  11. 11. Kovacs C. Galalac R: Promising treatment outcome, following high dose rate brachytherapy and external beam radiation in 189 men with localized prostate cancer. Book of Kiel \'leaching Course on LDR and HDR Prostate Brachytherapy 30.09-2.10.1999. Kiel, Germany.
  12. 12. Rogowski W, Łyczek J. Sieczych A. Wi¶niewski T. Demkow \'l\': Brachy-terapia HDR w leczeniu chorych z miejscowo niezaawansowanym rakiem gruczołu krokowego. Uroi Pol 2001; 2A: 33.
  13. 13. Wronczewski A. Wronczewska A, Wolski\'/„ MakarewiczR: Brachy-terapia HDR u chorydi z rakiem Stercza - wczesna ocena wyników. Uroi Pol 2001:2A: 34.
  14. 14. Han B. Demel K, Wallner K. Ellis W. Young L, Russell K: Patiem repor-led complications after prostatae brachytherapy. [Urol 2001:166: 953-957.
  15. 15. Stone NN. Stock RG: Complications following permanent prostate brachytherapy. Kur Uro 2002; 41:427-43 3.
  16. 16. Tapen E, Blasko J. Grimm P. Ragde H. Luse R. Clifford S: Reduction of radioactive seed embolization to lite bng following prostate brachytherapy. Int) Radial Oncol Biol Phys 1998: 42: 1963.
  17. 17. Talcott J. Clark J. Stark P Mitchell S: Long-term treatment related complications ofbrachytherapy for early prostate cancer a surgery of patients previously treated. J Urol 2001; 166:494-499.
  18. 18. Kestta I.. Golstein N, Vinci E Martinez A: Percentage of positive biopsy cores a predictor of clinical outcome in prostate cancer treated with radiotherapy. J Urol 2002:168: 1994-1999.
  19. 19. Smathers S. Wallner K: Temporary PSA rises and repeated prostate biopses after brachytherapy, Int J Radiat Oncol Biol Phys 2001: 50: 1207-1211.
  20. 20. Gretzer M, Trock B. Han M. Walsh: A criticalanalisisafter the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology Criteria. J Urol 2002:168; 1419-1422.


Zbigniew Wolski
Kalwini i Klinika Urologii Akademii Medycznej iv Bytlgossezg
ul, Al. Sklodmvskiej-Curii 9
85-094 Bydgoszcz
tel.fax:(0...52)585 4045